NO943451D0 - Anvendelse av mannosefosfater for behandling av fibrotiske sykdommer - Google Patents

Anvendelse av mannosefosfater for behandling av fibrotiske sykdommer

Info

Publication number
NO943451D0
NO943451D0 NO943451A NO943451A NO943451D0 NO 943451 D0 NO943451 D0 NO 943451D0 NO 943451 A NO943451 A NO 943451A NO 943451 A NO943451 A NO 943451A NO 943451 D0 NO943451 D0 NO 943451D0
Authority
NO
Norway
Prior art keywords
pct
treatment
mannose
phosphates
fibrotic diseases
Prior art date
Application number
NO943451A
Other languages
English (en)
Other versions
NO943451L (no
NO306808B1 (no
Inventor
Mark William James Ferguson
Original Assignee
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Tech Group filed Critical British Tech Group
Publication of NO943451L publication Critical patent/NO943451L/no
Publication of NO943451D0 publication Critical patent/NO943451D0/no
Publication of NO306808B1 publication Critical patent/NO306808B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO943451A 1992-03-17 1994-09-16 Anvendelse av mannosefosfater for behandling av fibrotiske sykdommer NO306808B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929205800A GB9205800D0 (en) 1992-03-17 1992-03-17 Treatment of fibrotic disorders
PCT/GB1993/000541 WO1993018777A1 (en) 1992-03-17 1993-03-16 Use of mannose phosphates for the treatment of fibrotic disorders

Publications (3)

Publication Number Publication Date
NO943451L NO943451L (no) 1994-09-16
NO943451D0 true NO943451D0 (no) 1994-09-16
NO306808B1 NO306808B1 (no) 1999-12-27

Family

ID=10712310

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943451A NO306808B1 (no) 1992-03-17 1994-09-16 Anvendelse av mannosefosfater for behandling av fibrotiske sykdommer

Country Status (18)

Country Link
US (1) US5520926A (no)
EP (1) EP0728006B1 (no)
JP (1) JP3930556B2 (no)
AT (1) ATE196847T1 (no)
AU (1) AU667887B2 (no)
CA (1) CA2130805C (no)
DE (1) DE69329559T2 (no)
DK (1) DK0728006T3 (no)
ES (1) ES2151903T3 (no)
GB (2) GB9205800D0 (no)
GR (1) GR3035117T3 (no)
IL (1) IL105079A (no)
NO (1) NO306808B1 (no)
NZ (1) NZ249915A (no)
PT (1) PT728006E (no)
SG (1) SG49899A1 (no)
WO (1) WO1993018777A1 (no)
ZA (1) ZA931869B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
SE9403137D0 (sv) * 1994-09-20 1994-09-20 Perstorp Ab Derivatives of carbohydrates and compositions containing them
US6566339B1 (en) 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB9516012D0 (en) * 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
GB9616896D0 (en) * 1996-08-12 1996-09-25 British Tech Group Pharmaceutical compositions
US6093388A (en) * 1996-08-12 2000-07-25 Btg International Limited Mannose-6-phosphate composition and its use in treating fibrotic disorders
DE19758059C2 (de) * 1997-12-29 2001-10-04 Thorsten Marquardt Verwendung von Mannose zur Bekämpfung der Proteinverlust-Enteropathie
WO2002030432A1 (en) * 2000-06-23 2002-04-18 Cambridgemed, Inc Agent for reduction of scar formation by using wound alkalinization
DE60142632D1 (de) * 2000-11-30 2010-09-02 Novodermix Internat Ltd Heilung von wunden
US20030031689A1 (en) * 2001-08-09 2003-02-13 Thomas Mammone Method of skin exfoliation
US6822033B2 (en) 2001-11-19 2004-11-23 United States Gypsum Company Compositions and methods for treating set gypsum
JP4564261B2 (ja) * 2002-01-22 2010-10-20 ジェンザイム、コーポレーション 慢性的移植片拒絶反応の治療と予防のためのＴＧＦ−β拮抗薬の使用
EP1507543A4 (en) * 2002-05-09 2006-07-26 Cambridgemed Inc PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF WOOD WITH BLOOD PLASMA OR SERUM
GB0217136D0 (en) 2002-07-24 2002-09-04 Renovo Ltd Wound healing & treatment of fibrosis
KR100492913B1 (ko) * 2002-08-23 2005-06-03 주식회사 태평양 피부 감작 및 자극을 완화하는 피부 외용제 조성물
US20050136126A1 (en) * 2003-03-17 2005-06-23 Cambridgemed, Inc. Agent for reduction of scar formation by using wound alkalinization
JP4634027B2 (ja) * 2003-05-16 2011-02-16 花王株式会社 ビタミンｄ様活性代替用剤
US7276486B2 (en) * 2004-03-15 2007-10-02 Kimberly-Clark Worldwide, Inc. Compositions for vaginal treatment
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
WO2006044433A2 (en) * 2004-10-13 2006-04-27 The Ohio State University Research Foundation Methods to treat or prevent viral-associated lymphoproliferative disorders
US20070048391A1 (en) * 2005-08-23 2007-03-01 Cambridgemed, Inc. Composition for reduction of scar formation on wound scar
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
EP1948675B1 (en) 2005-10-25 2014-07-30 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
EP2230252A1 (en) 2006-03-13 2010-09-22 The Johns Hopkins University Augmentation of endothelial thromboresistance
EP3254696A1 (en) 2006-10-03 2017-12-13 Genzyme Corporation Use of tgf beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
US8070895B2 (en) 2007-02-12 2011-12-06 United States Gypsum Company Water resistant cementitious article and method for preparing same
US8329308B2 (en) 2009-03-31 2012-12-11 United States Gypsum Company Cementitious article and method for preparing the same
GB0910078D0 (en) 2009-06-11 2009-07-22 Renovo Ltd Uses of mannose-6-phosphate
GB0916333D0 (en) 2009-09-17 2009-10-28 Renovo Ltd Improvement of tendon repair
GB0916334D0 (en) * 2009-09-17 2009-10-28 Renovo Ltd Inhibition of tendon adhesions
HUE027831T2 (en) 2010-03-12 2016-11-28 Genzyme Corp Combination therapy for breast cancer
US20140170236A1 (en) * 2010-11-05 2014-06-19 Priscilla Hayes Petty Use of phosphoric acid
CA2823154A1 (en) 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
MX2014004994A (es) 2011-10-26 2014-08-27 Seattle Children S Res Inst Cisteamina en el tratamiento de enfermedad fibrotica.
EP2799537B1 (en) 2011-12-28 2021-09-22 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
EP3064222B1 (en) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2023172636A1 (en) * 2022-03-08 2023-09-14 University Of Mississippi Medical Center Articles and methods for improved tissue healing
CN115260256A (zh) * 2022-07-22 2022-11-01 河南中医药大学 一种甘露糖磷酸化衍生物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756953A (fr) * 1969-10-02 1971-04-01 Merck & Co Inc Potentialisation d'antibiotiques
JPS5631156B2 (no) * 1973-09-25 1981-07-20
IT1170618B (it) * 1981-01-13 1987-06-03 Foscama Biomed Chim Farma Preparato farmacologico di frutto sio-1,6-difosfato ad azione terapeutica nei pazienti ustionati
US4703040A (en) * 1985-04-03 1987-10-27 Markov Angel K Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP)
ATE78166T1 (de) * 1985-10-22 1992-08-15 Silvetti Anthony N Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
US4889844A (en) * 1985-10-22 1989-12-26 Silvetti Sr Anthony N Fructose containing wound healing preparation
AU607690B2 (en) * 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
JPS62243675A (ja) * 1986-04-15 1987-10-24 Kao Corp ｐＨ緩衝法
ATE139699T1 (de) * 1988-08-19 1996-07-15 Univ Australian Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel
GB8917414D0 (en) * 1989-07-29 1989-09-13 Translift Material Handling Narrow aisle lift truck
WO1991004748A1 (en) * 1989-09-29 1991-04-18 La Jolla Cancer Research Foundation INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
SE8904354D0 (sv) * 1989-12-21 1989-12-21 Matti Siren A pharmaceutical composition
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
JPH0558868A (ja) * 1991-08-27 1993-03-09 Kao Corp 親水性紫外線吸収剤及びこれを含有する化粧料
AU3943793A (en) * 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
JPH09155319A (ja) * 1995-12-13 1997-06-17 Takeo Tsutsui 重金属含有焼却灰等、シュレッダーダストの無公害化処理方法および再利用材の製造方法

Also Published As

Publication number Publication date
DE69329559T2 (de) 2001-05-31
IL105079A0 (en) 1993-07-08
DE69329559D1 (de) 2000-11-16
EP0728006B1 (en) 2000-10-11
CA2130805A1 (en) 1993-09-30
ES2151903T3 (es) 2001-01-16
JP3930556B2 (ja) 2007-06-13
GB2265310B (en) 1996-09-25
ATE196847T1 (de) 2000-10-15
US5520926A (en) 1996-05-28
PT728006E (pt) 2001-04-30
WO1993018777A1 (en) 1993-09-30
JPH07504909A (ja) 1995-06-01
DK0728006T3 (da) 2000-10-30
NO943451L (no) 1994-09-16
AU3759093A (en) 1993-10-21
AU667887B2 (en) 1996-04-18
NO306808B1 (no) 1999-12-27
EP0728006A1 (en) 1996-08-28
IL105079A (en) 1998-06-15
NZ249915A (en) 1996-08-27
GB2265310A (en) 1993-09-29
GB9205800D0 (en) 1992-04-29
SG49899A1 (en) 1998-06-15
ZA931869B (en) 1994-09-16
GB9305344D0 (en) 1993-05-05
CA2130805C (en) 2003-06-24
GR3035117T3 (en) 2001-03-30

Similar Documents

Publication Publication Date Title
NO306808B1 (no) Anvendelse av mannosefosfater for behandling av fibrotiske sykdommer
NO307027B1 (no) Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader
FI970101A (fi) Uusi farmaseuttinen valmiste kivun hallintaan
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
AU5144396A (en) Trisubstituted phenyl derivatives
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
DE69424777T2 (de) 3,4-diarylchromane zur behandlung von dermatitis
EP0744176A3 (en) Methods for inhibiting bone loss
AU1278600A (en) Novel therapeutic application of nicergoline
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE254919T1 (de) Verwendung von penciclovir zur behandlung von menschlichem herpes virus-8
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
UA10259A (uk) Протинабряковий лікарський препарат "нейрополіосм"

Legal Events

Date Code Title Description
MK1K Patent expired